Filtros de búsqueda

Lista de obras de Francesco Passamonti

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

artículo científico publicado en 2008

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

artículo científico publicado en 2009

A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!

artículo científico publicado en 2019

A gain-of-function mutation of JAK2 in myeloproliferative disorders

artículo científico publicado en 2005

A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients

artículo científico publicado en 2007

A novel germline JAK2 mutation in familial myeloproliferative neoplasms.

artículo científico publicado en 2014

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

artículo científico publicado en 2014

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

artículo científico publicado en 2012

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

artículo científico publicado en 2010

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

artículo científico publicado en 2009

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

artículo científico publicado en 2013

Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.

artículo científico publicado en 2002

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

artículo científico publicado en 2005

Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies

artículo científico publicado en 2009

Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry.

artículo científico publicado en 2010

Balancing efficacy and safety of JAK inhibitors in myelofibrosis

artículo científico publicado en 2014

Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection.

artículo científico publicado en 2009

Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients

artículo científico publicado en 2001

Blast phase of essential thrombocythemia: A single center study

artículo científico publicado en 2009

Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis.

artículo científico publicado en 2008

Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia

artículo científico publicado en 2012

Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients

artículo científico publicado en 2008

Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations

artículo científico publicado en 2007

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

artículo científico publicado en 2014

COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

artículo científico publicado en 2022

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

artículo científico publicado en 2020

Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.

artículo científico publicado en 2014

Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases

scientific article published on 29 March 2014

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

artículo científico publicado en 2015

Classification of myeloproliferative neoplasms and prognostic factors

artículo científico publicado en 2012

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

artículo científico publicado en 2014

Clinical findings and diagnosis in a case of cholangiocellular carcinoma in a horse

scientific article published on 01 September 2008

Clinical predictors of outcome in MPN.

artículo científico

Clinical relevance of JAK2 (V617F) mutant allele burden

scientific article published on January 2009

Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes

artículo científico publicado en 2008

Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm

artículo científico publicado en 2011

Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders

artículo científico publicado en 2004

Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders

artículo científico publicado en 2003

Clinical, serological and molecular investigations of EHV-1 and EHV-4 in 15 unweaned thoroughbred foals.

artículo científico publicado en 2008

Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma

artículo científico publicado en 2004

Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment

scientific article published on 19 August 2005

Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.

artículo científico publicado en 2004

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

artículo científico publicado en 2010

Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.

artículo científico publicado en 2011

Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study)

artículo científico publicado en 2019

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

artículo científico publicado en 2010

Direct-acting Antivirals in Hepatitis C Virus-positive Mantle Cell Lymphomas

artículo científico publicado en 2020

Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

scientific article published on 28 April 2020

Disease anticipation in familial myeloproliferative neoplasms

artículo científico publicado en 2008

Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.

artículo científico publicado en 2012

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

artículo científico publicado en 2014

Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis

artículo científico publicado en 2010

Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia.

artículo científico publicado en 2006

Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma.

artículo científico publicado en 1998

Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene

artículo científico publicado en 2013

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

artículo científico publicado en 2016

Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations

artículo científico publicado en 2009

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment

artículo científico publicado en 2012

Everolimus in diffuse large B-cell lymphomas

artículo científico publicado en 2015

Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases.

artículo científico publicado en 2005

Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation

artículo científico publicado en 2007

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

artículo científico publicado en 2020

Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.

artículo científico publicado en 2011

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

artículo científico publicado en 2011

Germline RBBP6 mutations in familial myeloproliferative neoplasms.

artículo científico publicado en 2015

HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia

artículo científico publicado en 2007

Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

artículo científico publicado en 2013

High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma

artículo científico publicado en 2009

How I treat polycythemia vera

artículo científico publicado en 2012

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey

artículo científico publicado en 2020

How to manage polycythemia vera.

artículo científico publicado en 2011

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm

artículo científico publicado en 2011

Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper

artículo científico publicado en 2013

Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma

artículo científico publicado en 2008

Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.

artículo científico publicado en 2005

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

artículo científico publicado en 2015

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

artículo científico publicado en 2019

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts

artículo científico publicado en 2014

Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas

article

Improving survival trends in primary myelofibrosis: an international study

artículo científico publicado en 2012

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology

artículo científico publicado en 2014

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.

artículo científico publicado en 2011

Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence.

artículo científico publicado en 2010

Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia

artículo científico publicado en 2009

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

artículo científico publicado en 2010

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation

artículo científico publicado en 2007

Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.

artículo científico publicado en 2012

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma

artículo científico

It is time to change thrombosis risk assessment for PV and ET?

artículo científico

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative

artículo científico publicado en 2019

JAK inhibitor in CALR-mutant myelofibrosis

artículo científico publicado en 2014

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations ⬇️

artículo científico publicado el 16 de noviembre de 2010

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders

artículo científico publicado en 2006

JAK2 (V617F) mutation in healthy individuals

artículo científico publicado en 2007

Leukemia risk models in primary myelofibrosis: an International Working Group study

artículo científico publicado en 2012

Leukemic transformation of polycythemia vera: a single center study of 23 patients

artículo científico publicado en 2005

Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients

artículo científico publicado en 2012

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

scientific article published on 01 November 2004

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.

artículo científico publicado en 2008

Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up

scientific article published on 01 November 2006

Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman

artículo científico publicado en 2004

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

artículo científico publicado en 2012

Looking for CALR mutations in familial myeloproliferative neoplasms.

artículo científico publicado en 2014

Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma.

artículo científico publicado en 2013

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

artículo científico publicado en 2009

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

artículo científico publicado en 2011

Molecular detection, epidemiology, and genetic characterization of novel European field isolates of equine infectious anemia virus.

artículo científico publicado en 2010

Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation

artículo científico publicado en 2009

Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia.

artículo científico publicado en 2001

Mutational status of myeloproliferative neoplasms.

artículo científico publicado en 2010

Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.

artículo científico publicado en 2014

Myelofibrotic transformation in essential thrombocythemia. Author reply.

artículo científico publicado en 2009

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies ⬇️

artículo científico publicado el 1 de junio de 2011

New and old prognostic factors in polycythemia vera

artículo científico publicado en 2009

New generation small-molecule inhibitors in myeloproliferative neoplasms.

artículo científico publicado en 2012

New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms.

artículo científico publicado en 2016

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

scientific article published on 06 November 2008

New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma

artículo científico publicado en 2016

Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination

artículo científico publicado en 2006

Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders

artículo científico publicado en 2006

Novel agents in indolent lymphomas.

artículo científico publicado en 2013

PDGFRB disease: right diagnosis to prolong survival

artículo científico publicado en 2014

PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia

scientific article published on 01 May 2005

Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis

artículo científico publicado en 2015

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

artículo científico publicado en 2011

Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.

artículo científico publicado en 2002

Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases

artículo científico publicado en 2005

Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis

scientific article published on 13 October 2020

Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia.

artículo científico publicado en 2009

Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.

artículo científico publicado en 2003

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

artículo científico publicado en 2009

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

artículo científico publicado en 2015

Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT.

artículo científico publicado en 2006

Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy

artículo científico publicado en 2014

Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease.

artículo científico publicado en 2007

Prognostic Factors and Models in Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis ⬇️

artículo científico publicado el 29 de abril de 2011

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

artículo científico publicado en 2005

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

artículo científico publicado en 2008

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

artículo científico publicado en 2016

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment

scientific article published on 30 August 2007

Pulmonary rhodococcosis in a cat

artículo científico publicado en 2011

RBC-transfusion guidelines update

artículo científico publicado en 2012

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS ⬇️

artículo científico publicado el 30 de septiembre de 2010

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

artículo científico publicado en 2005

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

scientific article published on 10 March 2009

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.

artículo científico publicado en 2013

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients ⬇️

artículo científico publicado el 13 de abril de 2011

Risk of second cancer in nongastric marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue: a population-based study from northern Italy

scientific article published on 01 January 2007

Role of the molecular staging and response in the management of follicular lymphoma patients

scientific article published on 01 June 2006

Ruxolitinib and survival improvement in patients with myelofibrosis.

artículo científico publicado en 2014

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

artículo científico publicado en 2017

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

artículo científico

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

artículo científico publicado en 2015

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

artículo científico publicado en 2019

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

artículo científico publicado en 2007

Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles

artículo científico publicado en 2004

Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires

artículo científico publicado en 2009

Stem cell transplant in MF: it's time to personalize

artículo científico publicado en 2019

Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT.

artículo científico publicado en 2009

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

artículo científico publicado en 2011

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study ⬇️

artículo científico publicado el 6 de junio de 2013

Survival in young patients with intermediate- / high-risk myelofibrosis: estimates derived from databases for non transplant patients

scientific article published on 01 March 2009

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

artículo científico publicado en 2015

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

artículo científico publicado en 2009

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients

artículo científico publicado en 2011

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group

artículo científico publicado en 2016

The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms ⬇️

artículo científico publicado el 20 de diciembre de 2010

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

artículo científico publicado en 2013

Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity

scientific article published on 01 October 2000

Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman

artículo científico publicado en 2003

Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients

artículo científico publicado en 2014

Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms

artículo científico publicado en 2016

Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia

artículo científico publicado en 2014

Validation of cytogenetic-based risk stratification in primary myelofibrosis.

artículo científico publicado en 2010

Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients

artículo científico publicado en 2010

What are RBC-transfusion-dependence and -independence?

scientific article published on 07 August 2010

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda